2018
DOI: 10.1001/jamaoncol.2017.4526
|View full text |Cite
|
Sign up to set email alerts
|

EGFR–TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non–Small Cell Lung Cancer

Abstract: We found a higher proportion of reports of IP for nivolumab in combination with EGFR-TKI vs treatment with either drug alone. Owing to the limitations of this study, the results warrant further confirmation. However, careful consideration should be given to the possibility of an increased risk of IP when EGFR-TKI is administered in combination with nivolumab, including concomitant and sequential use, and careful monitoring for IP is recommended.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

3
179
1

Year Published

2018
2018
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 232 publications
(183 citation statements)
references
References 8 publications
3
179
1
Order By: Relevance
“…This study demonstrates a high prevalence of chronic pain among cancer survivors of all age categories, which should be addressed by oncologists, primary care physicians, and policymakers alike. Cancer treatment has also become increasingly complex, with many patients undergoing multimodality therapies that are associated with higher toxicity rates . Because of the direct medical costs of managing pain symptoms and indirect costs due to lost productivity, the high prevalence of chronic pain among cancer survivors likely contributes to a substantial national financial burden .…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…This study demonstrates a high prevalence of chronic pain among cancer survivors of all age categories, which should be addressed by oncologists, primary care physicians, and policymakers alike. Cancer treatment has also become increasingly complex, with many patients undergoing multimodality therapies that are associated with higher toxicity rates . Because of the direct medical costs of managing pain symptoms and indirect costs due to lost productivity, the high prevalence of chronic pain among cancer survivors likely contributes to a substantial national financial burden .…”
Section: Discussionmentioning
confidence: 99%
“…Cancer treatment has also become increasingly complex, with many patients undergoing multimodality therapies that are associated with higher toxicity rates. [14][15][16][17] Because of the direct medical costs of managing pain symptoms and indirect costs due to lost productivity, the high prevalence of chronic pain among cancer survivors likely contributes to a substantial national financial burden. 18 As such, our work should serve as an impetus for further research on the long-term health and psychosocial consequences related to patients' cancer diagnoses and treatments, including chronic pain.…”
Section: Discussionmentioning
confidence: 99%
“…Owing to the limitations of the FAERS database, our data only indicate an increased risk of aortic aneurysm or dissection with fluoroquinolones, requiring further confirmation.…”
Section: Discussionmentioning
confidence: 81%
“…Consistent with these results, previous studies have shown that the biological processes of the immune system are critical to the formation of a complicated LUAD tumor microenvironment 10,30,[37][38][39] . In the past few years, the understanding of the immunological characteristics of LUAD has increased, and the development of effective LUAD immunotherapy strategies has drawn wide attention [40][41][42][43][44] .…”
Section: Discussionmentioning
confidence: 99%